Clinical Classification, Screening and Diagnosis for Thalassemia

https://doi.org/10.1016/j.hoc.2017.11.006Get rights and content

Section snippets

Key points

  • Diagnosis of thalassemia and hemoglobinopathies requires a comprehensive evaluation combining red blood cell phenotypes, hemoglobin profiles, and DNA analysis.

  • A recent classification of thalassemia syndrome is based on the patients’ clinical severity that is their transfusion requirement, not genotypes.

  • Hemoglobin analysis can be performed at any age; however, interpretation requires age-specific reference ranges.

  • Genetic analysis for globin mutations are required to confirm the clinical

Clinical classification of thalassemia

Disorders of hemoglobin (Hb) are characterized according to pathologic defects on globin chain production; a quantitative defect or “thalassemia,” mainly α-thalassemia and β-thalassemia, and a qualitative defect, namely hemoglobinopathy (or structural Hb variants), and, last, hereditary persistence of fetal Hb. Interactions of these 3 types of globin defects result in a wide array of thalassemia syndromes and related diseases.1

Thalassemia has a wide spectrum of clinical severity, which was

Screening and diagnosis of thalassemia

In general, the screening and diagnostic algorithm for thalassemia can be divided into 2 levels—population and individual—in which different approaches have been implemented owing to different objectives of screening. The screening methods used in a population approach that focused on identification of thalassemia and Hb variant traits are described. Last, comprehensive diagnostic tests for thalassemia confirmation are discussed. All currently available laboratory tests for screening and

Summary

Thalassemia diseases are classified into TDT and NTDT, based on patients’ clinical severity whether they require regular blood transfusions to survive (TDT) or not (NTDT). Screening and definitive diagnoses of thalassemia and hemoglobinopathies require a comprehensive evaluation, from clinical history, physical examination, and laboratory results, including a complete blood count, Hb profiles, and molecular studies. There are several screening tools used in population screening. Clinicians need

First page preview

First page preview
Click to open first page preview

References (78)

  • A.N. Barrett et al.

    Thalassaemia screening and confirmation of carriers in parents

    Best Pract Res Clin Obstet Gynaecol

    (2017)
  • N. Sae-ung et al.

    Phenotypic expression of hemoglobins A(2), E and F in various hemoglobin E related disorders

    Blood Cells Mol Dis

    (2012)
  • A.S. Tan et al.

    A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for alpha-thalassemia

    Blood

    (2001)
  • P. Sutcharitchan et al.

    Reverse dot-blot detection of the African-American beta-thalassemia mutations

    Blood

    (1995)
  • C.C. Hung et al.

    Molecular assay of -alpha(3.7) and -alpha(4.2) deletions causing alpha-thalassemia by denaturing high-performance liquid chromatography

    Clin Biochem

    (2007)
  • W. Chinchang et al.

    Molecular analysis of unknown beta-globin gene mutations using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and its application in Thai families with beta-thalassemias and beta-globin variants

    Clin Biochem

    (2005)
  • A. Blattner et al.

    Detection of germline rearrangements in patients with alpha- and beta-thalassemia using high resolution array CGH

    Blood Cells Mol Dis

    (2013)
  • V. Viprakasit et al.

    Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia

    Blood

    (2004)
  • D.J. Weatherall et al.

    The thalassaemia syndromes

    (2001)
  • M.D. Cappellini et al.

    Guidelines for the clinical management of thalassaemia

    (2008)
  • V. Viprakasit

    Alpha thalassemia syndromes: from clinical and molecular diagnosis to bedside management

    EHA Hematol Educ Program

    (2013)
  • V. Chan et al.

    Molecular defects in Hb H hydrops fetalis

    Br J Haematol

    (1997)
  • S. He et al.

    Hb H Hydrops Fetalis Syndrome Caused by Association of the - -(SEA) Deletion and Hb Constant Spring (HBA2: c.427T > C) Mutation in a Chinese Family

    Hemoglobin

    (2015)
  • D.Z. Li et al.

    Hemoglobin H hydrops fetalis syndrome resulting from the association of the - -SEA deletion and the alphaQuong Szealpha mutation in a Chinese woman

    Eur J Haematol

    (2005)
  • J. Li et al.

    Phenotypic variability in a Chinese family with nondeletional Hb H-Hb Quong Sze disease

    Hemoglobin

    (2011)
  • F. Lorey et al.

    Hb H hydrops foetalis syndrome: a case report and review of literature

    Br J Haematol

    (2001)
  • K.L. McBride et al.

    Hb Dartmouth [alpha66(E15)Leu-->Pro (alpha2) (CTG-->CCG)]: a novel alpha2-globin gene mutation associated with severe neonatal anemia when inherited in trans with Southeast Asian alpha-thalassemia-1

    Hemoglobin

    (2001)
  • V. Viprakasit et al.

    Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of alpha thalassaemia (–MED/(alpha)TSaudi(alpha))

    Br J Haematol

    (2002)
  • N.Z. Zainal et al.

    alpha-Thalassemia with Haemoglobin Adana mutation: prenatal diagnosis

    Malays J Pathol

    (2014)
  • V. Viprakasit et al.

    Genetic basis, pathophysiology and diagnosis [Chapter 1]

  • M. de Montalembert et al.

    Partial splenectomy in homozygous beta thalassaemia

    Arch Dis Child

    (1990)
  • A.T. Taher et al.

    When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia

    Vox Sang

    (2015)
  • A.T. Taher et al.

    Optimal management of beta thalassaemia intermedia

    Br J Haematol

    (2011)
  • V. Viprakasit et al.

    Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition

    Orphanet J Rare Dis

    (2014)
  • G. Fucharoen et al.

    A simplified screening strategy for thalassaemia and haemoglobin E in rural communities in south-east Asia

    Bull World Health Organ

    (2004)
  • E. Silvestroni et al.

    Screening for microcytemia in Italy: analysis of data collected in the past 30 years

    Am J Hum Genet

    (1975)
  • C.L. Harteveld

    State of the art and new developments in molecular diagnostics for hemoglobinopathies in multiethnic societies

    Int J Lab Hematol

    (2014)
  • Cited by (122)

    View all citing articles on Scopus

    Disclosure Statement: All authors have nothing to declare.

    View full text